Intercept Pharmaceuticals
Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
Morristown, United States
376 employees
Post-IPO Debt
Total: $970.05M
Biotechnology, Health Care +1
General Information
Morristown, United States
BounceWatch is an independent company data service, not affiliated with Intercept Pharmaceuticals. To contact Intercept Pharmaceuticals, visit interceptpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Intercept Pharmaceuticals compare?
A PDF of Intercept Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Intercept Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Intercept Pharmaceuticals on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Intercept Pharmaceuticals
Business keywords: Biopharmaceutical, Liver diseases, Rare diseases, Drug development, Therapeutics, Chronic autoimmune liver diseases, Small molecule drugs, Fibrotic diseases, Metabolic diseases, Bile acid receptors, Chronic liver diseases, Non-viral liver diseases, Innovation
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Debt | $447.70M | - |
|
30 Jun 2016 |
| Post IPO Equity | $338.40M | - |
|
01 Apr 2015 |
| Post IPO Equity | $61.70M | - |
|
17 Jun 2013 |
| Series C | $30.00M | 3 |
|
10 Aug 2012 |
| Series B | $25.00M | 1 |
|
25 Jan 2010 |
| Series A | $25.00M | 1 |
|
29 Jul 2008 |
| Venture Round | $41.00M | 3 |
|
16 May 2006 |
| Debt Financing | $1.25M | 1 |
|
04 May 2005 |
Latest News
View All
Intercept Pharmaceuticals Alternatives & Competitors
View All Alternatives
Dedicated to improving the lives of patients with liver diseases
Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical...
East Meets West—The Quest for Cure
FAQ About Intercept Pharmaceuticals
Source: BounceWatch company record for Intercept Pharmaceuticals, https://bouncewatch.com/company/intercept-pharmaceuticals, updated 31 December 2024. When citing, please name BounceWatch and link this page.
